Substituted heteroaryl- and phenylsulfamoyl compounds

Details Substituted heteroaryl- and phenylsulfamoyl compounds Substituted heteroaryl- and phenylsulfamoyl compounds

C - Chemistry, Metallurgy

07

C

C07C 311/21 (2006.01) C07C 311/44 (2006.01) C07C 323/49 (2006.01) C07D 213/75 (2006.01) C07D 215/12 (2006.01) C07D 231/12 (2006.01) C07D 235/18 (2006.01) C07D 263/54 (2006.01) C07D 271/06 (2006.01) C07D 277/62 (2006.01) C07D 285/00 (2006.01) C07D 307/79 (2006.01) C07D 333/58 (2006.01)

Patent

CA 2559035

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

La présente invention concerne des composés hétéroaryle et phénylsulfamoyle substitués, les compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés comme agonistes du récepteur activateur proliférateur de péroxisome (PPAR). L'invention concerne également des activateurs alpha PPAR, les compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés pour augmenter certains niveaux de lipides plasmatiques, y compris le cholestérol lipoprotéine haute densité et réduire d'autres niveaux lipides plasmatiques, tels que le cholestérol LDL et les triglycérides et conformément de traiter des maladies exacerbées par de faibles niveaux de cholestrol HDL et/ou des niveaux élevés de cholestérol LDL et triglycérides, tels que l'athérosclérose et des maladies cardiovasculaires, chez les mammifères, y compris les êtres humains. Ces composés sont utiles pour le traitement d'un bilan énergétique négatif (NEB) et de maladies associées chez les ruminants.

Affiliated with

Also associated with

Rating

Substituted heteroaryl- and phenylsulfamoyl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heteroaryl- and phenylsulfamoyl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heteroaryl- and phenylsulfamoyl compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1907084